Can-Fite BioPharma (CANF) Receivables - Other (2013 - 2022)
Can-Fite BioPharma's (CANF) quarterly Receivables - Other came in at $1.2 million in Q4 2022, up 25.94% YoY from $929000.0 in Q4 2021, and up 25.94% on a QoQ basis from $929000.0 in Q4 2021.
Can-Fite BioPharma (CANF) Receivables - Other (2013 - 2022) Analysis & Trends
Can-Fite BioPharma (CANF) has 9 years of Receivables - Other data on file, last reported at $1.2 million in Q4 2022.
- Quarterly Receivables - Other rose 25.94% year-over-year to $1.2 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $1.2 million (up 25.94% YoY) and the FY2022 annual result came in at $1.2 million, up 25.94% from the prior year.
- Receivables - Other rose to $1.2 million in Q4 2022, from $929000.0 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $4.4 million in Q4 2019 to a low of $929000.0 in Q4 2021.
- A 5-year average of $2.4 million and a median of $1.8 million in 2019 frame the typical range for Receivables - Other.
- Annual changes were most pronounced in 2018 — Receivables - Other grew 27.1% — and 2020, when it sank 75.88%.
- Tracing CANF's Receivables - Other over 5 years: stood at $4.0 million in 2018, then grew by 9.17% to $4.4 million in 2019, then slumped by 75.88% to $1.1 million in 2020, then declined by 12.11% to $929000.0 in 2021, then increased by 25.94% to $1.2 million in 2022.
- The last three Receivables - Other figures came in at $1.2 million (Q4 2022), $929000.0 (Q4 2021), and $1.1 million (Q4 2020), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.84 Bn | 131.99 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.48 Bn | 78.49 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn |
| 4 | Moderna | 60.15 Bn | 55.01 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.54 Bn | 10.14 Bn | 668.28 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.22 Bn | 26.38 Bn | - |
| 10 | Can-Fite BioPharma | 2.77 Mn | -8.78 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 1.17 Mn |
| Dec 31, 2022 | 1.17 Mn |
| Dec 31, 2021 | 929,000.00 |
| Dec 31, 2021 | 929,000.00 |
| Dec 31, 2020 | 1.06 Mn |
| Dec 31, 2020 | 1.06 Mn |
| Dec 31, 2019 | 4.38 Mn |
| Dec 31, 2019 | 4.38 Mn |
| Sep 30, 2019 | 1.75 Mn |
| Sep 30, 2019 | 1.75 Mn |
| Dec 31, 2018 | 4.02 Mn |
| Dec 31, 2018 | 4.02 Mn |
| Jun 30, 2018 | 3.29 Mn |
| Jun 30, 2018 | 3.29 Mn |
| Dec 31, 2017 | 3.16 Mn |
| Dec 31, 2017 | 3.16 Mn |
| Dec 31, 2016 | 2.01 Mn |
| Dec 31, 2016 | 2.01 Mn |
| Mar 31, 2014 | 5.64 Mn |
| Mar 31, 2014 | 5.64 Mn |